The Nitrogen Is Bonded Directly At The 17-position Patents (Class 552/522)
-
Patent number: 10087211Abstract: This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage.Type: GrantFiled: November 2, 2016Date of Patent: October 2, 2018Assignees: RESEARCH TRIANGLE INSTITUTE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Scott P. Runyon, Michael Rogawski, Edgar Cook, John Kepler, Hernan Navarro, Rafal Kaminski, Matthew Orr
-
Patent number: 9518080Abstract: This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage.Type: GrantFiled: August 23, 2013Date of Patent: December 13, 2016Assignees: RESEARCH TRIANGLE INSTITUTE, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Scott P Runyon, Michael Rogawski, Edgar Cook, John Kepler, Hernan Navarro, Rafal Kaminski, Matthew Orr
-
Patent number: 9266815Abstract: Disclosed herein are novel motuporamine compounds that act as anti-metastatic agents with low toxicity and high anti-migration activity. The non-toxic, anti-metastatic agents may be given to patients with potential or actual metastatic cancers, such as pancreatic cancers, alone in combination with known and/or new therapies to help block the growth and spread of tumor(s).Type: GrantFiled: March 13, 2013Date of Patent: February 23, 2016Assignee: University of Central Florida Research Foundation, Inc.Inventors: Otto Phanstiel, IV, Aaron Muth
-
NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME
Publication number: 20140235600Abstract: The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: December 18, 2013Publication date: August 21, 2014Applicant: Washington UniversityInventors: Douglas Covey, Albert Jean Robichaud -
Publication number: 20140094619Abstract: This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage.Type: ApplicationFiled: August 23, 2013Publication date: April 3, 2014Applicants: US GOV BY THE SEC. OF DEPT. OF HEALTH & HUMAN SERV, RESEARCH TRIANGLE INSTITUTEInventors: Scott P. RUNYON, Michael ROGAWSKI, Edgar COOK, John KEPLER, Hernan NAVARRO, Rafal KAMINSKI, Matthew ORR
-
Patent number: 8586770Abstract: The invention relates to methods to manipulate stem cells in vivo and in vitro to treat, e.g., a condition where cell or tissue repair is needed.Type: GrantFiled: February 18, 2011Date of Patent: November 19, 2013Assignee: Harbor Therapeutics, Inc.Inventor: James M. Frincke
-
Patent number: 8575375Abstract: This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage.Type: GrantFiled: June 16, 2008Date of Patent: November 5, 2013Assignees: Research Triangle Institute, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Scott P. Runyon, Michael A. Rogawski, John Kepler, Hernan Navarro, Rafal Kaminski, Matthew Orr, Kevin M. Cook
-
Patent number: 8569275Abstract: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.Type: GrantFiled: April 27, 2011Date of Patent: October 29, 2013Assignee: Harbor Therapeutics, Inc.Inventor: James M. Frincke
-
Publication number: 20130266645Abstract: The present invention relates to compounds derived from steroids of the general formula (I) wherein L represents a linker and R# represents a steroid residue, the use of compounds of the general formula (I) in medicine and for the prophylaxis and/or the treatment of infectious diseases. Furthermore described are pharmaceutical compositions containing at least one compound of the general formula (I). A further aspect of the invention relates to the synthesis of said compounds of the general formula (I).Type: ApplicationFiled: October 6, 2011Publication date: October 10, 2013Applicant: Justus-Liebig-Universitat GiessenInventors: Katja Becker, Reimar Krieg, Bruno Schönecker
-
Publication number: 20110212935Abstract: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.Type: ApplicationFiled: April 27, 2011Publication date: September 1, 2011Applicant: Harbor BioSciences, Inc.Inventor: James M. Frincke
-
Publication number: 20110092473Abstract: This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage.Type: ApplicationFiled: June 16, 2008Publication date: April 21, 2011Applicants: Research Triangle Institute, US GOV BY THE SEC. OF DEPT. OF HEALTH & HUMAN SERV.Inventors: Scott P. Runyon, Michael Rogawski, Edgar Cook, Kevin M. Cook, John Kepler, Hernan Navarro, Rafal Kaminski, Matthew Orr
-
Patent number: 7910571Abstract: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.Type: GrantFiled: October 13, 2006Date of Patent: March 22, 2011Assignee: Harbor BioSciences, Inc.Inventor: James M. Frincke
-
Publication number: 20100069627Abstract: The invention relates to a diastereoselective method for obtaining a primary amine on a steroid, comprising the reduction of an oxime by lithium in ammonia at a low temperature in an ether/alcohol mixture.Type: ApplicationFiled: June 12, 2009Publication date: March 18, 2010Applicant: SANOFI-AVENTISInventors: Gilles ODDON, Daniel BERNARD, Gerard CAZENAVE, Andre SIMONNET, Joelle BOUSQUET-FRANCES
-
Patent number: 7135581Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: wherein the variables are defined in the specification.Type: GrantFiled: August 24, 2001Date of Patent: November 14, 2006Assignee: Entremed, Inc.Inventors: Gregory E. Agoston, Jamshed H. Shah, Kimberly A. Hunsucker, Victor S. Pribluda, Theresa M. LaVallee, Shawn J. Green, Christopher J. Herbstritt, Xiaoguo H. Zhan, Anthony M. Treston
-
Patent number: 6995278Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: wherein the variables are defined in the specification.Type: GrantFiled: February 8, 2001Date of Patent: February 7, 2006Assignee: Entre Med, Inc.Inventors: Gregory E. Agoston, Victor Pribluda, Anthony M. Treston, Shawn J. Green
-
Patent number: 6562805Abstract: The present invention relates to methods, compounds and compositions for inhibiting effective binding of a chemokine to its cellular receptor. In one form of the invention, a method includes contacting a cellular population with an effective amount of cosalane or an analog thereof. The invention further relates to methods, compounds and compositions for treating inflammatory diseases. In one form, a method includes administering to a patient a therapeutically effective amount of cosalane or an analog thereof.Type: GrantFiled: January 29, 2001Date of Patent: May 13, 2003Assignees: Purdue Research Foundation, The United States of America as represented by the Department of Health and Human ServicesInventors: Mark S. Cushman, O. M. Zack Howard
-
Patent number: 6436918Abstract: Novel sulfatase inhibitor compounds useful in the treatment of estrogen dependent illnesses are disclosed. These compounds generally comprise a steroid nucleus substituted at the C17 position. Methods for synthesizing these compounds and using them in the therapeutic and/or prophylactic treatment of a patient are also disclosed.Type: GrantFiled: November 8, 2001Date of Patent: August 20, 2002Assignees: Duquesne University of the Holy Ghost, Kyowa Hakko Kogyo Co., Ltd.Inventors: Pui-Kai Li, Chikara Murakata, Shiro Akinaga
-
Patent number: 6399595Abstract: Novel sulfatase inhibitor compounds useful in the treatment of estrogen dependent illnesses are disclosed. These compounds generally comprise a steroid nucleus substituted at the C17 position. Methods for synthesizing these compounds and using them in the therapeutic and/or prophylactic treatment of a patient are also disclosed.Type: GrantFiled: August 3, 2001Date of Patent: June 4, 2002Assignees: Duquesne University of the Holy Ghost, Kyowa Hakko Kogyo Co., Ltd.Inventors: Pui-Kai Li, Chikara Murakata, Shiro Akinaga
-
Patent number: 6262042Abstract: The invention is directed to a novel class of steroids which exhibit potent antiprogestational activity.Type: GrantFiled: May 29, 1998Date of Patent: July 17, 2001Assignee: Research Triangle InstituteInventors: C. Edgar Cook, John A. Kepler, Gary S. Bartley
-
Patent number: 6136992Abstract: Compounds represented by the following structural formula: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification. The compounds are disclosed as useful in the treatment of various forms of cancer.Type: GrantFiled: March 12, 1998Date of Patent: October 24, 2000Assignees: The United States of America as represented by the Department of Health and Human Services, Pharm-Eco Laboratories, IncorporatedInventors: Siya Ram, Ravi Varma, Yesh Sachdeva
-
Patent number: 6093707Abstract: The invention is directed to a novel class of steroids which exhibit potent antiprogestational activity.Type: GrantFiled: November 5, 1999Date of Patent: July 25, 2000Assignee: Research Triangle InstituteInventors: C. Edgar Cook, John A. Kepler, Rupa S. Shetty, Gary S. Bartley, David Yue-wei Lee
-
Patent number: 5990328Abstract: The present invention provides 4-nitro-.DELTA..sup.4 -3-ketosteroids, their use as steroid C.sub.17-20 lyase and 5.alpha.-reductase inhibitors and to a novel process for preparing a compound of the formula: ##STR1## comprising sequentially: a) reacting a starting compound of the formula ##STR2## with an effective amount of a strong base at an elevated or suitable temperature for a time sufficient to create the corresponding thermodynamic dienolate, followed by addition of a neutral nitrating agent to produce the 4-nitrosteroid; and then;b) reacting the 4-nitrosteroid with a suitable reducing agent.Type: GrantFiled: February 24, 1999Date of Patent: November 23, 1999Assignee: Merrell Pharmaceuticals Inc.Inventors: Philip M. Weintraub, Michael R. Angelastro, Cynthia A. Gates, Gary Alan Flynn, Timothy Thomas Curran, Chi-Hsin Richard King
-
Patent number: 5965550Abstract: The invention discloses 3-ketosteroids of the following formula used to inhibit steroid C.sub.17-20 lyase: ##STR1## wherein R is OH, C.sub.1 -C.sub.6 alkanoyl, C.sub.1 -C.sub.6 alkanoyloxy, C.sub.1 -C.sub.4 alkanol, COCH.sub.2 OH, CO.sub.2 H, CONR.sub.7 R.sub.8, cyclopropyloxy, cyclopropylamino, acetylthioalkane, 2,2-dimethyldioxolan4-yl, 1,2-dihydroxyethyl and C.sub.1-4 alkylthiol;R.sub.1 is hydrogen, hydroxy or C.sub.1-6 alkyl;R and R.sub.1 together may indicate .dbd.O, that is an oxygen double bonded to the 17 carbon;R.sub.2, R.sub.3, and R.sub.4 are each independently hydrogen or C.sub.1 -C.sub.6 alkyl;R.sub.5 and R.sub.6 are each independently hydrogen or OH;R.sub.5 and R.sub.6 together may indicate .dbd.O, that is an oxygen double bonded to the 11 carbon;R.sub.7 is hydrogen or C.sub.1 -C.sub.8 alkyl;R.sub.8 is C.sub.1 -C.sub.8 alkyl; andwith the proviso that, when R is OH, then R.sub.1 is hydrogen; andwith the proviso that, when R.sub.5 is OH, then R.sub.6 is hydrogen.Type: GrantFiled: January 22, 1998Date of Patent: October 12, 1999Assignee: Merrell Pharmaceuticals Inc.Inventors: Philip M. Weintraub, Michael R. Angelastro, Cynthia A. Gates, Timothy Thomas Curran, Gary Alan Flynn, Chi-Hsin Richard King
-
Patent number: 5910478Abstract: The present invention provides peptides, cyclized peptides and peptidomimetics which inhibit the oncogenic and/or transforming activity of the p21 ras protein, pharmaceutical compositions containing at least one of the ras-inhibiting peptides, cyclized peptides and peptidomimetics, and methods for inhibiting the ras-mediated oncogenic and/or transformation process in mammalian cells or tissues.Type: GrantFiled: September 20, 1996Date of Patent: June 8, 1999Assignee: Innapharma, Inc.Inventors: Joseph J. Hlavka, John Fowler Noble, Henry Baxter Abajian, Andrew S. Kende, Matthew R. Pincus
-
Patent number: 5892069Abstract: The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods.Type: GrantFiled: April 25, 1997Date of Patent: April 6, 1999Assignee: The Children's Medical Center CorporationInventors: Robert John D'Amato, Moses Judah Folkman
-
Patent number: 5880115Abstract: Sulfatase inhibitor compounds having the formula: ##STR1## wherein X, Y, R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification. The compounds are useful in the treatment of estrogen dependent illnesses. Methods for synthesizing these compounds are also disclosed.Type: GrantFiled: July 18, 1997Date of Patent: March 9, 1999Assignee: Duquesne University of the Holy GhostInventors: Pui-Kai Li, Kyle W. Selcer
-
Patent number: 5621123Abstract: Provided are cyclic hydrocarbons of Formula I ##STR1## with an aminoalkyl sidechain that are useful for treating phospholipase A2 mediated conditions, diabetes, and obesity.Type: GrantFiled: May 20, 1994Date of Patent: April 15, 1997Assignee: The Upjohn CompanyInventors: Roy A. Johnson, Gordon L. Bundy, Gilbert A. Youngdale, Douglas R. Morton, Donald P. Wallach, deceased, Vera M. Wallach, legal representative
-
Patent number: 5599806Abstract: The invention describes hydrazino and hydroxyamino-14.beta.-hydroxyandrostane derivatives having general formula (I): ##STR1## wherein the symbol means .alpha. or .beta. configuration and A, B, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 have the meanings given in the description and their use in the treatment of cardiovascular disorders such as heart failure and hypertension.Type: GrantFiled: May 18, 1995Date of Patent: February 4, 1997Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Alberto Cerri, Giuseppe Bianchi, Patrizia Ferrari, Elena Folpini, Piero Melloni
-
Patent number: 5439899Abstract: Novel compounds having anti-HIV activity are disclosed along with formulations and methods for treating human immunodeficiency viral infections employing these compounds.Type: GrantFiled: March 10, 1993Date of Patent: August 8, 1995Assignees: Purdue Research Foundation, The United States of America as represented by the Department of Health and Human ServicesInventors: Mark Cushman, Rudiger D. Haugwitz, Wieslaw M. Golebiewski
-
Patent number: 5372996Abstract: A method of treatment of androgen-related diseases such as prostate cancer in susceptible male animals, including humans, comprises administering novel antiandrogens and/or novel sex steroid biosynthesis inhibitors as part of a combination therapy. Sex steroid biosynthesis inhibitors, especially those capable of inhibiting conversion of dehydroepiandrosterone (DHEA) or 4-androstenedione (.DELTA..sup.4 -dione) to natural sex steroida (and testosterone into dihydrotestosterone) in peripheral tissues, are used in combination with antiandrogens usually after blockade of testicular hormonal secretions. Antiestrogens can also be part of the combination therapy. Pharmaceutical compositions and two, three, four and five component kits are useful for such combination treatment.Type: GrantFiled: October 19, 1992Date of Patent: December 13, 1994Assignee: Endorecherche, Inc.Inventor: Fernand Labrie
-
Patent number: 5334712Abstract: Provided are cyclic hydrocarbons of Formula I ##STR1## with an aminoalkyl sidechain that are useful for treating phospholipase A2 mediated conditions, diabetes, and obesity.Type: GrantFiled: November 16, 1992Date of Patent: August 2, 1994Assignee: The Upjohn CompanyInventors: Roy A. Johnson, Gordon L. Bundy, Gilbert A. Youngdale, Douglas R. Morton, Donald P. Wallach, deceased
-
Patent number: 5274089Abstract: Provided are cyclic hydrocarbons of Formula I ##STR1## with an aminoalkyl sidechain that are useful for treating phospholipase A2 mediated conditions, diabetes, and obesity.Type: GrantFiled: November 6, 1992Date of Patent: December 28, 1993Assignee: The Upjohn CompanyInventors: Gordon L. Bundy, Donald P. Wallach, deceased
-
Patent number: 5187299Abstract: Provided are cyclic hydrocarbons of Formula I ##STR1## with an aminoalkyl sidechain.Type: GrantFiled: November 13, 1991Date of Patent: February 16, 1993Assignee: The Upjohn CompanyInventors: Roy A. Johnson, Gordon L. Bundy, Gilbert A. Youngdale, Douglas R. Morton, Donald P. Wallach, deceased, Wallach, Legal Representative, by Vera M.
-
Patent number: 5157031Type: GrantFiled: March 21, 1989Date of Patent: October 20, 1992Assignee: Research Corporation Technologies, Inc.Inventors: Arthur G. Schwartz, Marvin L. Lewbart
-
Patent number: 5093502Abstract: A process for the preparation of novel 14.alpha., 17.alpha.-dihydroxy-17.beta.-substituted steroids by reacting 14.alpha.-hydroxy-17-oxo-steroids with metal organic compounds and the use of the said novel steroids in the production of 14.alpha., 17.alpha.-methylenedioxy-pregnane derivatives.Type: GrantFiled: February 16, 1990Date of Patent: March 3, 1992Assignee: Akzo N.V.Inventors: Peter M. Smid, Willem J. Van Zoest, Pieter G. Weber, Arthur F. Marx
-
Patent number: 5075464Abstract: This invention is directed to 17.beta.-(cyclopropylamino)androstenes and also to a method for using such compounds in the treatment of androgen-dependent disorders. The compounds are prepared by the hydride reduction of an appropriate steroidal imine or enamine.Type: GrantFiled: June 14, 1989Date of Patent: December 24, 1991Assignee: Merrell Dow Pharmaceuticals Inc.Inventors: Thomas R. Blohm, Michael R. Angelastro
-
Patent number: 5075434Abstract: This invention is a compound of formula 1 and pharmaceutically acceptable salts thereof; ##STR1## wherein R.sub.1 is fluorine, chlorine or bromine; wherein R.sub.2 is hydrogen or (C.sub.1 -C.sub.3) alkyl; wherein n is one or 2; wherein R.sub.3 is phenyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl; wherein phenyl is optionally substituted with one substituent selected from the group consisting of halogen, trifluoromethyl or sulfonamide. These compounds are useful as hypoglycemic agents.Type: GrantFiled: September 20, 1990Date of Patent: December 24, 1991Assignee: The Upjohn CompanyInventor: Gilbert A. Youngdale
-
Patent number: 4966898Abstract: This invention is directed to 4-substituted 17.beta.-(cyclopropylamino)androst-5-en-3.beta.-ol and related compounds and also to a method for using such compounds in the treatment of androgen-dependent disorders. The compounds are prepared by the hydride reduction of an appropriate steroidal imine or enamine.Type: GrantFiled: August 15, 1989Date of Patent: October 30, 1990Assignee: Merrell Dow Pharmaceuticals Inc.Inventors: Michael R. Angelastro, Thomas R. Blohm
-
Patent number: 4954446Abstract: Invented are substituted acrylate analogues of steroidal synthetic compounds, pharmaceutial compositions containing the compounds, and methods of using these compounds to inhibit steroid 5-.alpha.-reductase including using these compounds to reduce prostate size. Also invented are intermediates used in preparing these compounds.Type: GrantFiled: July 14, 1989Date of Patent: September 4, 1990Assignee: SmithKline Beecham CorporationInventors: Dennis A. Holt, Mark A. Levy, Brian W. Metcalf
-
Patent number: 4917826Abstract: Provided are cyclic hydrocarbons of Formula I ##STR1## with an aminoalkyl sidechain that are useful for treating phospholipase A2 mediated conditions, diabetes, and obesity.Type: GrantFiled: June 16, 1987Date of Patent: April 17, 1990Assignee: The Upjohn CompanyInventors: Roy A. Johnson, Gordon L. Bundy, Gilbert A. Youngdale, Douglas R. Morton, Donald P. Wallach, deceased
-
Patent number: RE47750Abstract: Disclosed herein are novel motuporamine compounds that act as anti-metastatic agents with low toxicity and high anti-migration activity. The non-toxic, anti-metastatic agents may be given to patients with potential or actual metastatic cancers, such as pancreatic cancers, alone in combination with known and/or new therapies to help block the growth and spread of tumor(s).Type: GrantFiled: February 22, 2018Date of Patent: December 3, 2019Assignee: University of Central Florida Research Foundation, Inc.Inventors: Otto Phanstiel, IV, Aaron Muth